NICE are shortly going to carry out an appraisal of Mepoluzimab for treating EGPA (CSS) . If you have EGPA which has not responded to the “usual” treatment, ie you have refactory EGPA and it has had a major impact on your life and you would like to share your experience, please contact John Mills John.mills@vasculitis.org.uk
Extracts from these personal patient experiences maybe used in the vasculitis UK submission to the NICE appraisal committee
Thank you